Mutual of America Capital Management LLC Sells 3,048 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Mutual of America Capital Management LLC decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 5.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,573 shares of the company’s stock after selling 3,048 shares during the quarter. Mutual of America Capital Management LLC owned approximately 0.05% of Neurocrine Biosciences worth $6,288,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of NBIX. 1832 Asset Management L.P. raised its position in shares of Neurocrine Biosciences by 1,370.7% during the second quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock valued at $74,507,000 after buying an additional 504,400 shares during the last quarter. Los Angeles Capital Management LLC raised its holdings in Neurocrine Biosciences by 639.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after acquiring an additional 363,863 shares in the last quarter. AQR Capital Management LLC raised its holdings in Neurocrine Biosciences by 23.0% in the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock valued at $166,959,000 after acquiring an additional 228,444 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Neurocrine Biosciences by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock worth $1,369,673,000 after acquiring an additional 220,598 shares during the period. Finally, Iron Triangle Partners LP acquired a new stake in shares of Neurocrine Biosciences during the 1st quarter worth approximately $30,342,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Up 1.3 %

NASDAQ:NBIX opened at $119.13 on Wednesday. Neurocrine Biosciences, Inc. has a 1 year low of $108.14 and a 1 year high of $157.98. The stock has a 50-day moving average price of $118.44 and a two-hundred day moving average price of $132.40. The stock has a market cap of $12.06 billion, a price-to-earnings ratio of 31.94 and a beta of 0.35.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on NBIX. Jefferies Financial Group boosted their price target on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a report on Monday, August 19th. HC Wainwright reissued a “buy” rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a research report on Friday, November 1st. Raymond James reaffirmed an “outperform” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. Finally, Piper Sandler upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $131.00 to $159.00 in a research report on Thursday, August 29th. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.